Around the same time details of T-cell lymphoma in a 51-year old male treated for refractory/relapsed multiple myeloma, with Ciltacabtagene Autoleucel (Cilta-cel, LV anti-BCMA CAR T cells, Carvykti ®) [65], a licenced anti-BCMA (B-cell Maturation Antigen) SIN-LV CAR-T cell therapy were reported with evidence of T-cell clonality 5 months after a second wave of CAR-T expansion with lymphadenopathy and new onset skin lesions suggestive of T-cell infiltration. Here, TNFRSF17 is linked to Lymphadenopathy.